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 2 
Abstract 26 
 27 
Rodent scrapie models have been exploited to define the molecular basis for the progression of 28 
neuropathological changes in TSE diseases. We aim to assess whether CNS gene expression 29 
changes consistently observed in mouse models are of generic relevance, for example to natural 30 
TSE diseases, or are TSE strain, host species or brain region specific. Six genes, representing 31 
distinct physiological pathways and showing consistent changes in expression levels with disease 32 
progression in murine scrapie models were analysed for expression (RT-qPCR) in defined regions 33 
of the sheep brain at various times after SSBP/1 scrapie infection. Gene expression was examined 34 
in relation to the development of neuropathological changes including PrP
Sc
 deposition and 35 
vacuolation.  Peripheral infection of sheep with SSBP/1 showed consistent progression of 36 
neuropathology as assessed by the temporal course of PrP
Sc
 deposition and neuropil vacuolation. 37 
The first region affected was the medulla (obex), then the thalamus and finally the cerebellum and 38 
frontal cortex. In contrast to mouse scrapie, there were few significant changes in transcript 39 
expression for any of the six genes and no consistent changes in patterns of expression in relation 40 
to brain region, time after infection or neuropathology in sheep SSBP/1. Gene expression changes 41 
in mouse TSE models, even changes consistent with the neuropathology, cannot necessarily be 42 
extrapolated to species in which disease naturally occurs. This may represent differences in 43 
pathological processes of different scrapie strains or across species; and highlights the difficulties 44 
in identifying generic molecular pathways associated to the pathogenesis of TSE disease. 45 
46 
 3 
1.  Introduction 47 
 48 
Scrapie is a sheep transmissible spongiform encephalopathy (TSE). TSEs are fatal 49 
neurodegenerative diseases that also include bovine spongiform encephalopathy (BSE) and 50 
human Creutzfeldt-Jakob disease (CJD). A characteristic feature of TSEs is the conversion of the 51 
membrane glycoprotein PrP (PrP
C
) to disease-associated, insoluble PrP
Sc
. The central role for PrP 52 
in TSE pathogenesis is illustrated by the resistance to disease of PrP-null mice (Bueler et al., 53 
1993), by the inverse association of incubation period with PrP gene (PRNP) copy number 54 
(Bueler et al., 1993; Manson et al., 1994) and by the fact that susceptibility and resistance to 55 
sheep scrapie infection is largely controlled by polymorphisms of PRNP at codons 136 (V or A), 56 
154 (R or H) and 171 (R or Q,). With the scrapie strain SSBP/1, VRQ homozygous sheep have a 57 
short incubation period; ARR homozygotes are resistant and heterozygotes have intermediate 58 
incubation periods (Houston et al., 2002).  Different TSE diseases and scrapie strains can be 59 
differentiated by their distinct and reproducible incubation period lengths and characteristic 60 
patterns of PrP
Sc
 deposition and pathology, including astrocytosis and neuropil vacuolation 61 
(Jeffrey and González, 2007).  62 
Gene expression profiling, largely of murine scrapie (Xiang et al., 2004; Riemer et al., 63 
2004; Brown et al., 2004; Brown et al., 2005; Xiang et al., 2007; Hwang et al., 2009) or terminal 64 
human CJD (Xiang et al., 2005) has been used to elucidate the molecular basis for TSE diseases 65 
and to identify possible therapeutic targets (Hwang et al., 2009). Studies on mouse scrapie, 66 
largely using whole brain preparations, have identified genes that change in expression level in 67 
the brain with disease progression (Hwang et al., 2009). However, it is not known if these 68 
changes are of generic relevance and occur in relation to diseases progression in scrapie in its 69 
natural sheep host or if they are only relevant for the individual model. 70 
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Six genes showing consistent changes in mouse models of scrapie and chosen to 71 
represent disparate physiological pathways were analysed for expression in sheep infected with 72 
SSBP/1 scrapie. The genes chosen for this study were C1QB, CCL5 (SCYA5 or RANTES), CCR5, 73 
NCKAP1, EGR1 and FDFT1. The progressive increase in brain-expressed transcripts for the first 74 
component of the classical complement pathway - C1q during the development of murine and 75 
hamster scrapie, has been a common finding in several studies (Dandoy-Dron et al., 1998; Riemer 76 
et al., 2000; Brown et al., 2004; Brown et al., 2005; Skinner et al., 2006; Hwang et al., 2009). 77 
C1q is one of three C1q subunits and has been implicated in the localization of PrPSc, from the 78 
site of infection to splenic follicular dendritic cells (Mabbott et al., 2001). Transcripts for the 79 
chemokine/receptor pair CCL5 and CCR5 are significantly increased in the hippocampus at late 80 
stage disease in ME7 scrapie -infected mice; it is postulated that they exacerbate 81 
neurodegeneration by amplifying proinflammatory responses (Lee et al., 2005). NCKAP1 (Nck-82 
associated protein 1) and EGR1 (early growth response gene 1) are both significantly reduced in 83 
mouse scrapie (Booth et al., 2004); however NCKAP1 is pro-apoptotic and is repressed in human 84 
Alzheimer’s disease (Yamamoto et al., 2001), while EGR1 is growth promoting and anti-85 
apoptotic (Virolle et al., 2003) and is increased in Alzheimer’s disease (Marella et al., 2005). 86 
FDFT1 (farnesyl-diphosphate farnesyltransferase 1 or squalene synthetase) is an important 87 
enzyme in cholesterol metabolism and its repression in mouse scrapie (Riemer et al., 2004; Xiang 88 
et al., 2007; Hwang et al., 2009) is thought to indicate a link between age-related and scrapie-89 
associated neurodegeneration.  90 
SSBP/1 scrapie (Wilson et al., 1950) is a commonly-used scrapie isolate in sheep (Foster 91 
et al., 2001; Houston et al., 2002) because of the well defined link between incubation period and 92 
PRNP genotype (Hunter, 2007) and is the parent of many commonly used rodent strains including 93 
22C, 139A, RML and 263K (Kimberlin et al., 1989). This project investigated the progression of 94 
disease, as defined by PrP
Sc
 deposition and neuropil vacuolation, induced by SSBP/1 in four 95 
defined regions of the CNS in sheep of defined PRNP genotypes (VRQ/VRQ, VRQ/ARR and 96 
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ARR/ARR) with differential susceptibility to scrapie disease. To determine if TSE - associated 97 
molecular signatures for the progression of disease in mice are of generic relevance to TSE 98 
pathogenesis, gene expression levels of the six putative disease-associated genes from mouse 99 
studies were correlated to neuropathology in susceptible VRQ/VRQ sheep. 100 
 101 
2.  Materials and methods 102 
 103 
2.1. Scrapie infection, histology and immunohistology 104 
 105 
New Zealand Cheviot sheep of the PRNP genotypes VRQ/VRQ, VRQ/ARR and 106 
ARR/ARR were from the DEFRA breeding flock (Houston et al., 2002).  All were inoculated 107 
subcutaneously with 2 ml of 10% w/v brain homogenate; for each genotype at each time point 108 
three were infected with SSBP/1scrapie and two mock-infected with normal brain. VRQ/VRQ 109 
animals were killed by exsanguination under terminal anaesthesia at 10, 25, 50, 75, 100 and 125 110 
days post-infection (dpi) and at clinical stage. The same protocol was followed for sheep of the 111 
other PRNP genotypes with additional time points at 150 and 230 dpi (VRQ/ARR and 112 
ARR/ARR) and 1200 dpi (only ARR/ARR). ARR/ARR animals are resistant and there was no 113 
clinical group for this genotype. Brains were removed immediately post mortem, four brain 114 
regions were dissected (medulla (obex), thalamus, cerebellum and frontal cortex) and tissue 115 
blocks placed in RNAlater (Qiagen, Crawley, UK) prior to storage at -80ºC, or fixed in neutral 116 
buffered formalin. Animal experiments were approved by BBSRC Institute for Animal Health 117 
Ethical Review Committee and conducted under an Animals (Scientific Procedures) Act 1986 118 
Project Licence. Sections were stained using hematoxylin and eosin or the anti-PrP antibody BG4 119 
(epitope 46-54, N terminus; TSE Resource Centre, The Roslin Institute) (Jeffrey et al., 2001) 120 
using ABC peroxidase/Vector Nova Red by the hydrated autoclaving method for disease-related 121 
PrP (Foster et al., 2001).   122 
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 123 
2.2. Gene expression analysis 124 
 125 
Frozen brain tissue was converted to powder using a Mikro-Dismembrator U (Sartorius, 126 
Aubagne Cedex, Fr) and total RNA prepared using RNeasy Lipid Tissue Mini Kit (Qiagen) 127 
including DNase I digestion; RNA quality was assessed using a RNA Nano 6000 kit on the 128 
Agilent 2100 Bioanalyser and quantified using a NanoDrop ND-1000 Spectrophotometer. RT 129 
reactions were performed with 1 µg of total RNA from each sample with an anchored oligo(dT)20 130 
primer (Invitrogen, Paisley, UK) and M-MLV reverse transcriptase (Promega, Southampton, 131 
UK). A sample without RT was included as control. 132 
Gene-specific primers (Table 1) were designed using Primer3 (Rozen and Skaletsky, 133 
2000) and Net Primer (http://www.premierbiosoft.com/ netprimer/index.html). BLAST searches 134 
were performed for all primer sequences to confirm gene specificity prior to synthesis (Sigma-135 
Aldrich, Poole, UK.). Quantitative real-time RT-PCR (RT-qPCR) was performed in a Rotor-136 
Gene™ 3000 (Qiagen) using FastStart Taq DNA Polymerase (Roche Diagnostics Ltd., Lewes, 137 
UK) with SYBR green detection in a final volume of 20 µl. Amplification conditions used were 138 
the same for all genes; 5 min at 94ºC, followed by 40 cycles of 20 s at 94ºC, 20 s at 62ºC and 20 s 139 
at 72ºC. All reactions were performed in triplicate and ‘no template’ controls included for each 140 
gene. The cycle threshold value (Cq) was determined using the Rotorgene Software 6.0.34. 141 
Agarose gel electrophoresis and melt curve analysis confirmed single products, sequence analysis 142 
confirmed specificity.  The linearity and efficiency of RT-qPCR amplification was determined for 143 
each primer pair using a standard curve generated by a dilution series of a pool of sample cDNAs 144 
for each tissue. Several genes were evaluated for expression stability and suitability as 145 
endogenous reference genes for each of the different tissues using GeNorm v3.4 (Vandesompele 146 
et al., 2002) and NormFinder v 0.953 (Andersen et al., 2004). Gene expression levels were 147 
calculated using a modified ΔΔ-Cq method implemented in qBase analysis software (Hellemans 148 
 7 
et al., 2007). Relative quantities of each of the six target gene transcripts were calculated using 149 
the normalized quantities rescaled relative to the same calibrator (the same mock-infected control 150 
sheep for each brain area but with different control sheep for each time point). Statistical analyses 151 
were performed on data from individual animals using Kolmogorov-Smirnov to test for normality 152 
of distribution; the mean normalized expression values from the infected and mock infected 153 
groups were compared using unpaired t-tests, with Welch's correction. Data are presented as 154 
mean fold change, mock-infected versus infected. 155 
 156 
 157 
3.  Results 158 
 159 
3.1. Histopathology of the central nervous system 160 
 161 
Vacuolar degeneration and PrP
Sc
 deposition were determined in the medulla, thalamus, 162 
cerebellum and frontal cortex of scrapie susceptible and scrapie resistant sheep at time points 163 
after infection with SSBP/1 scrapie; incubation periods were 193 ± 12 dpi for VRQ/VRQ and 328 164 
± 36 dpi for VRQ/ARR sheep.  Evidence of low grade vacuolation was detected only in the 165 
susceptible VRQ/VRQ and VRQ/ARR genotypes and only at terminal disease time points (data 166 
not shown). The vacuolation that did occur was in the medullary and thalamic nuclei and was less 167 
conspicuous in VRQ/VRQ than in VRQ/ARR sheep. In contrast, PrP
Sc
 accumulation was detected 168 
in the susceptible animals at preclinical stages. In VRQ/VRQ sheep, PrP
Sc
 was first seen by 125 169 
dpi (Table 2) in the medulla in 3 of 3 infected animals and in the thalamus in 1 of 3; and in the 170 
medulla of VRQ/ARR sheep by 230 dpi in 1 of 3 infected animals. By the time of onset of 171 
clinical disease PrP
Sc
 was detected in all four brain areas of all infected, susceptible animals (Fig. 172 
1). Vacuolation and PrP
Sc
 deposition were not observed in mock-infected sheep or in sheep of the 173 
ARR/ARR genotype.  174 
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 175 
3.2. Gene expression analysis in four brain regions 176 
 177 
Based on consistent changes in gene expression in mouse TSE models, the levels of 178 
transcripts of six genes, C1QB, CCL5, CCR5, EGR1, NCKAP1 and FDFT1, were determined in 179 
each of the four brain areas in which pathological changes had been observed in SSBP/1 infected 180 
VRQ/VRQ sheep; the medulla, thalamus, cerebellum and frontal cortex. The quantification of 181 
gene expression in tissues requires the use of reference genes to normalize transcript numbers 182 
between different samples. Since brain regions could show considerable difference in gene 183 
expression, the stability of expression of several commonly used reference genes was first 184 
investigated across the four brain regions. Two reference genes from different functional classes 185 
were selected for each brain region, taking into account both intra- and inter-group variations. 186 
SDHA and YWHAZ were used for the medulla, cerebellum and frontal cortex, with SDHA and 187 
GAPDH for the thalamus (Table 3). 188 
Analysis of expression levels of transcripts for the six target genes revealed that most 189 
significant changes occurred after PrP
Sc
 deposition (Tables 2 and 4). C1QB showed no consistent 190 
alterations in transcript expression between brain regions or within any one region over time; the 191 
only significant changes were a 7-fold increase in the thalamus and an 8-fold reduction in the 192 
cerebellum at the clinical disease time point. CCL5 transcript levels were generally raised (1.27 - 193 
2.94 fold) in medulla, thalamus and cerebellum at the earliest three time points after infection (P 194 
≤ 0.05 only at 125 dpi in the thalamus and 75 dpi in the cerebellum), but reduced at the clinical 195 
time point in all four brain areas (P ≤0.05 only in medulla and frontal cortex). CCR5 expression 196 
levels were variable at different time points and between different brain regions; showing a small, 197 
but significant increase (1.6-fold, P ≤0.03) at 75 dpi in the medulla and 1.9-fold (P ≤ 0.01) at 125 198 
dpi in the thalamus.  Similarly variable and inconsistent over time within each region and 199 
between regions at each time point were the expression levels of EGR1, FDFT1 and NCKAP1, 200 
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which showed no obvious pattern of expression changes in relation to the progression of the 201 
neuropathology. The anti-apoptotic EGR1 was largely unchanged or repressed throughout the 202 
course of infection in all four brain areas, but P ≤ 0.05 only at 25 dpi in the cerebellum; EGR1 203 
was also strongly repressed at the clinical time point (except cerebellum) but P ≥ 0.2 in each case. 204 
The pro-apoptotic NCKAP1 was largely unchanged or increased through the course of infection, 205 
but P ≤ 0.05 only at 125 dpi in the thalamus and at clinical time points in the medulla and 206 
cerebellum. The gene associated with cholesterol metabolism FDFT1, which was significantly 207 
raised (2.57-fold) only at 25 dpi in the cerebellum was significantly reduced (–2.63-fold) at the 208 
clinical time point in the medulla; it was also repressed (–5.14-fold) at the clinical time point in 209 
the cerebellum but P = 0.17.  210 
 211 
4.  Discussion 212 
 213 
The unifying feature of the TSE family of diseases is that they are transmissible 214 
neurodegenerative diseases which are generally associated with PrP
Sc
 deposition.  Other 215 
neuropathological changes include gliosis, spongiosis, neuropil vacuolation and neuronal loss. 216 
However, not all TSEs are identical; each has a variable and characteristic combination of these 217 
different features (DeArmond and Ironside, 1999). Furthermore, within each susceptible species 218 
there are different strains of TSEs that have unique incubation periods and distinctive 219 
neuropathological profiles. Recently, a mouse/scrapie strain combination has been identified that 220 
has little quantitative association with PrP
Sc
 deposition (Barron et al., 2007). Nevertheless, 221 
pathologically distinct prion strains give rise to similar profiles of behavioural deficits 222 
(Cunningham et al., 2005). 223 
High throughput gene expression profiling of scrapie-infected brains has been used by 224 
several laboratories to quantify differentially expressed genes to try and identify a generic TSE 225 
profile in order to: (1) understand the molecular basis of TSE pathogenesis (Riemer et al., 2004; 226 
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Brown et al., 2005; Xiang et al., 2007; Tamgüney et al., 2008; Hwang et al., 2009); (2) identify 227 
novel risk genes and therapeutic targets (Xiang et al., 2004); (3) identify potential biomarkers of 228 
infection (Booth et al., 2004). All these studies have used rodent scrapie models with the 229 
presumption that results can be extrapolated to natural TSEs in target species (e.g. sheep, cattle 230 
and humans). The most extensive of these studies (Hwang et al., 2009) identified 333 transcripts 231 
that were commonly differentially expressed in three scrapie strains, in at least one of six mouse 232 
strains and at different time points during the course of disease. C1QB was represented in this 233 
group; and like the other genes that encode the C1q molecule, C1QA and C1QG, it showed a 234 
consistent and progressive increase in expression through the course of disease. An NCKAP1-like 235 
gene was also identified in this group and showed significantly reduced expression during scrapie 236 
disease.  237 
Our data show that in SSBP/1 scrapie in sheep there is a distinct progression of pathology 238 
within the brain; PrP
Sc
 accumulation is detected earliest in the medulla and thalamus and this 239 
eventually progresses to the cerebellum and frontal cortex. However, unlike murine ME7, RML 240 
or 139A and many human TSEs (DeArmond and Ironside, 1999), SSBP/1 shows few signs of 241 
astrocytosis and little and variable vacuolation (Foster et al., 1996; Begara-McGorum et al., 242 
2002). These differences in pathological features could explain the variation in gene profiles of 243 
the mouse and sheep diseases. 244 
In mice, transcripts for the chemokine CCL5 and its receptor CCR5 are up-regulated 245 
during terminal ME7-disease (Lee et al., 2005) and expression of C1QB increases in an 246 
approximate linear manner in the hippocampus during the progressive development of ME7 247 
scrapie (Brown et al., 2004). These three transcripts are probably products of astrocyte and 248 
microglial activation and their progressive increase in rodent ME7 infection is probably a result 249 
of the progressive gliosis which occurs in this system (Outram et al., 1973).  Significant changes 250 
were seen in sheep SSBP/1 with both CCL5 and CCR5 although there was no consistent pattern 251 
to these changes, either between regions or within any one region in relation to progression of 252 
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disease.  CCL5 might also be a neuronal product (Patterson et al., 2003) and the down-regulation 253 
at the clinical time point could be a result of the large-scale neuronal cell loss seen in terminal 254 
SSBP/1 scrapie (Foster et al., 2001). The variability is consistent with previous observations that 255 
progressive gliosis is a variable part of SSBP/1 pathology (Begara-McGorum et al., 2002) in 256 
sheep.  257 
Murine scrapie induces reduced expression of both the pro-apoptotic gene NCKAP1 and 258 
the anti-apoptotic EGR1 (Booth et al., 2004). NCKAP1 is expressed predominantly in neuronal 259 
cells (Suzuki et al., 2000) and is markedly reduced in human Alzheimer’s disease. EGR1 is a zinc 260 
finger transcription factor induced in neurons after extracellular stimulation with 261 
neurotransmitters or trophic substances; indeed amyloidosis in Alzheimer’s disease has been 262 
shown to increase EGR1 expression (MacGibbon et al., 1997) leading to the up-regulation of 263 
CCL5, possibly by neurons, explaining recruitment of microglia (Marella et al., 2005). Again, 264 
there was no consistent significant change or consistent trend in the expression of these two genes 265 
in sheep across either brain regions or with time, possibly because spongiosis and neuropil 266 
vacuolation are highly variable in SSBP/1 scrapie  and correlate poorly with PrP
Sc
 deposition 267 
(Foster et al., 1996; Begara-McGorum et al., 2002).  268 
Cholesterol has been shown to be important in the conversion of PrP
C
 to PrP
Sc
. Several 269 
enzymes of the cholesterol biosynthesis pathway have been shown to be differentially-regulated 270 
during both preclinical (Brown et al., 2005) and terminal murine scrapie (Riemer et al., 2004) and 271 
in Alzheimer’s disease (Ehehalt et al., 2003) and this has been taken as evidence that alterations 272 
in cholesterol metabolism may be a common consequence of amyloidogenic processes in both 273 
diseases (Brown et al., 2004). The results reported here are inconsistent with this hypothesis as 274 
expression levels of FDFT1 (an important enzyme in the cholesterol biosynthesis pathway) did 275 
not correlate with the development of SSBP/1 scrapie and were only significantly reduced at the 276 
clinical time point in the medulla. FDFT1 levels were significantly raised at 25 dpi in the 277 
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cerebellum, but this is unlikely to be of biological significance as PrP
Sc
 deposition was not 278 
detectable in the CNS at this time point.  279 
Although only six selected genes were used in this study it is clear that results of 280 
transcriptome analysis in scrapie must be interpreted and extrapolated with care and each model 281 
must be studied separately to find commonalities that may truly define the fundamental disease 282 
process.  283 
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Figure legends 416 
 417 
Fig.  1.   Immunohistological staining for PrP
Sc
 with the BG4 antibody of VRQ/VRQ sheep 418 
brain at clinical time point with SSBP/1 scrapie. (A) medulla (obex); (B) thalamus; (C) 419 
cerebellum and (D) frontal cortex. Magnification x10. 420 
Table 1.  Primers for real-time qRT-PCR  
 
Gene  Forward primer 5’ → 3’ Reverse primer 5’ → 3’ 
Primer 
(nM) 
Mg
2+
 
(mM) 
Size 
(bp) 
*qPCR 
efficiency 
       
GAPDH GGTGATGCTGGTGCTGAGTA TCATAAGTCCCTCCACGATG 300 3.5 265 95% 
       
SDHA ACCTGATGCTTTGTGCTCTGC CCTGGATGGGCTTGGAGTAA 300 2 126 98% 
       
YWHAZ TGTAGGAGCCCGTAGGTCATC TCTCTCTGTATTCTCGAGCCATC 600 3 101 94% 
       
CCL5 CGCCAACCCAGAGAAGAAGT CGCCACAAAGTTCAGGTTCAA 300 2.5 91 96% 
       
CCR5 ATACGTGCAGCCCACATTTC GATTCCCGAGTAGCAGACGA 600 2.5 98 99% 
       
C1QB AACGAGAATGGCGAGAAGG CAGGTGGTGGTTGATGGTG 300 3 191 95% 
       
FDFT1 ACTGTCACTATGTTGCTGGTC CCTTCTCGCTGGTCTTCC 600 3 169 100% 
       
EGR1 CCACCTCCTACTCCTCTCCTG CCATCTCCTCCTCCTGTCCT 300 3 282 99% 
       
NCKAP1 CAAGAGCAAGAGCTGGACATC AACTCGCCACCAGGACTTAGAG 600 3 108 98% 
       
 
* Reaction efficiency was calculated using the equation E=10
(-1/slope)
-1.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1
Table 2.  Immunohistology for PrP
Sc
 of PRNP genotype-sheep challenged with SSBP/1 
scrapie 
 
                             Brain Region  
dpi 
PRNP 
genotype 
Medulla Thalamus Cerebellum 
Frontal  
cortex 
100 VRQ/VRQ 0/0 0/0 0/0 0/0 
 VRQ/ARR 0/0 0/0 0/0 0/0 
      
125 VRQ/VRQ 3/3 1/3 0/3 0/3 
 VRQ/ARR 0/3 0/3 0/3 0/3 
      
150 VRQ/ARR 0/3 0/3 0/3 0/3 
      
230 VRQ/ARR 1/3 0/3 0/3 0/3 
      
Clinical 193 VRQ/VRQ 3/3 3/3 3/3 3/3 
             328 VRQ/ARR 3/3 3/3 3/3 3/3 
Shaded rows are time points with PrP
Sc
 accumulation. 
Table 2
Table 3.   Reference gene expression stability in four brain regions.  
 
Gene  Medulla Thalamus Cerebellum Frontal cortex 
GAPDH 0.083* 0.045 0.111 0.111 
SDHA 0.073 0.037 0.050 0.050 
YWHAZ 0.065 0.136 0.069 0.098 
 
* Gene expression normalization factor calculated by GeNorm and NormFinder; lowest value is 
most stable (least variable). Bold are the best combination of two genes for particular brain 
region.  
 
Table 3
Table 4.  Transcript expression levels in brain of scrapie VRQ/VRQ infected sheep 
 
 Medulla (obex) Thalamus Cerebellum           Frontal Cortex 
dpi 25 75 125 clin* 25 75 125 clin 25 75 125 clin 25 75 125 clin 
C1QB
‡
                 
Fold 2.55 1.01 -1.31 1.85 
†
 
†
 
†
 7.01 1.05 1.21 -1.10 -8.06 -1.49 -1.26 -1.2 -1.35 
P value 0.08 0.98 0.73 0.21 
† † † <0.01 0.96 0.59 0.87 <0.01 0.06 0.75 0.79 0.61 
CCL5                 
Fold 2.16 1.27 1.54 -2.06 2.94 1.90 2.30 -3.47 1.55 2.21 1.30 -17.38 1.09 -1.12 1.12 -3.66 
P value 0.27 0.72 0.07 <0.03 0.06 0.06 <0.05 0.24 0.07 <0.01 0.56 0.27 0.86 0.8 0.84 <0.01 
CCR5                 
Fold 1.31 1.60 -1.23 -1.34 1.92 1.15 1.90 1.49 -1.89 -1.06 1.12 -8.84 1.86 1.37 -1.29 -2.16 
P value 0.61 <0.03 0.18 0.18 0.22 0.76 <0.01 0.31 0.34 0.88 0.77 0.13 0.19 0.56 0.07 0.03 
EGR1                 
Fold 1.26 -1.91 1.10 -2.87 -2.20 1.06 1.32 -25.82 1.01 1.10 1.01 1.22 -2.28 -1.51 -1.03 -4.6 
P value 0.77 0.10 0.92 0.22 0.10 0.87 0.46 0.33 0.99 0.79 0.98 0.48 <0.05 0.68 0.91 0.34 
NCKAP1                 
Fold -1.11 -1.02 1.48 2.89 1.24 1.07 1.44 -1.62 -1.25 -1.22 1.26 6.32 -1.14 -1.75 1.16 2.27 
P value 0.62 0.69 0.41 <0.01 0.41 0.83 <0.02 0.32 0.41 0.16 0.41 <0.01 0.58 0.45 0.70 0.12 
FDFT1                 
Fold 1.45 1.05 -1.08 -2.63 1.10 1.07 1.35 -1.16 2.57 1.42 
†
 -5.14 -1.39 1.07 -1.34 1.29 
P value 0.20 0.72 0.74 <0.02 0.52 0.85 0.38 0.41 <0.01 0.44 
†
 0.17 0.17 0.64 0.13 0.53 
 
* clinical disease time point 193 ±  12 dpi . 
‡ 
Data are expressed as fold change, scrapie infected vs mock infected. 
† 
Below level of detection limit.  
 P values shown in bold are significant P ≤ 0.05. Shaded columns are time points with PrPSc accumulation. 
Table 4
Figure 1
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